2359:HKG
WuXi AppTec Ord Shs H
HK$208.00
0.00%
(0.00) 1D
Sep 21, 4:08:34 PM GMT+8 · HKD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Mkt. cap
593.77B
Avg. vol.
5.13M
Volume
0.00
Dividend
1.15%
Quarterly dividend
HK$0.60
Ex-dividend date
Sep 4, 2026
P/E ratio
25.49
52-wk high
HK$212.80
52-wk low
HK$96.70
EPS
HK$8.16
No. of employees
36K
Mkt. cap
593.77B
Avg. vol.
5.13M
Volume
0.00
Dividend
1.15%
Quarterly dividend
HK$0.60
Ex-dividend date
Sep 4, 2026
P/E ratio
25.49
52-wk high
HK$212.80
52-wk low
HK$96.70
EPS
HK$8.16
No. of employees
36K
News stories
From web sources and news partners
TipRanks
·
13 hours ago
WuXi AppTec Accommodates Late Bond Conversions Ahead of 2026 Early Redemption
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35.6K
FoundedDec 1, 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn